SA Pharmacy, Women's and Children's Hospital, North Adelaide, South Australia, Australia.
School of Public Health, University of Adelaide, Robinson Institute, Adelaide, South Australia, Australia.
Arch Dis Child. 2019 Sep;104(9):890-894. doi: 10.1136/archdischild-2018-316303. Epub 2019 May 11.
Non-adherence to treatment in childhood chronic illness has serious consequences for health and healthcare costs. Accurate detailed objective data on adherence are minimal in this age group.
To evaluate medication adherence using electronic monitoring systems in children with type 1 diabetes (T1D).
A cohort study of 90 T1D children (aged 13.6±2.5 years, 41 males) from two paediatric diabetes clinics, participated in a 12-month double-blind, randomised, placebo-controlled trial (1:1 allocation). This cohort provided 28 336 days of study observations; 7138 school holiday and 8875 weekend/public holiday days.
Adherence to intervention (metformin (n=45) or placebo (n=45)) was measured objectively by Medication Event Monitoring Systems (MEMS) including proportion of medication doses taken and daily adherence patterns and by tablet count at 3, 6 and 12 months. The trial was completed in June 2015.
There was an average (SD) of 363.3 (42) days of MEMS observations available for each study participant (94.1 (12.6) school holiday days and 117.1 (13.4) weekend/public holiday days). Adherence reduced during school holidays (adjusted OR (aOR) 0.81; 95% CI 0.72 to 0.91; p<0.001) and during weekends/public holidays (aOR 0.74; 95% CI 0.69 to 0.80; p<0.001). Adverse effects to the intervention did not affect overall adherence (aOR 0.77; 95% CI 0.3 to 2.01; p=0.6). Age, gender, body mass index, diabetes duration, insulin dose, HbA1c (Haemoglobin A1c) or socioeconomic status did not predict adherence.
Medication adherence was reduced during school holidays and on weekends in children with T1D. Clinical characteristics including socioeconomic status and the presence of adverse effects did not predict adherence.
ACTRN12611000148976.
儿童期慢性疾病治疗不依从会对健康和医疗费用产生严重后果。在这个年龄段,关于依从性的准确详细的客观数据很少。
使用电子监测系统评估 1 型糖尿病(T1D)儿童的药物依从性。
对来自两个儿科糖尿病诊所的 90 名 T1D 儿童(年龄 13.6±2.5 岁,男性 41 名)进行了一项队列研究,他们参加了为期 12 个月的双盲、随机、安慰剂对照试验(1:1 分配)。该队列提供了 28336 天的研究观察结果;7138 个学校假期和 8875 个周末/公共假日。
通过 Medication Event Monitoring Systems(MEMS)客观测量依从性(包括服用药物剂量的比例和每日依从模式)和 3、6 和 12 个月时的药片计数,干预措施(二甲双胍(n=45)或安慰剂(n=45))。该试验于 2015 年 6 月完成。
每位研究参与者平均(SD)有 363.3(42)天的 MEMS 观察结果(94.1(12.6)个学校假期和 117.1(13.4)个周末/公共假日)。在学校假期期间(调整后的 OR(aOR)0.81;95%CI 0.72 至 0.91;p<0.001)和周末/公共假日期间(aOR 0.74;95%CI 0.69 至 0.80;p<0.001),依从性降低。干预的不良反应并未影响整体依从性(aOR 0.77;95%CI 0.3 至 2.01;p=0.6)。年龄、性别、体重指数、糖尿病持续时间、胰岛素剂量、HbA1c(糖化血红蛋白)或社会经济地位均不能预测依从性。
在 T1D 儿童中,在学校假期和周末期间,药物依从性降低。临床特征,包括社会经济地位和不良反应的存在,不能预测依从性。
ACTRN12611000148976。